Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-interventional Prospective Observational Study Assessing APRemilast in psOriatic Arthritis in Real-life Clinical Practice in Greek Healthcare Environment. The "APROACH" Study

Next Previous
Trial Profile

A Non-interventional Prospective Observational Study Assessing APRemilast in psOriatic Arthritis in Real-life Clinical Practice in Greek Healthcare Environment. The "APROACH" Study

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms APROACH
  • Sponsors Genesis Pharma

Most Recent Events

  • 14 Nov 2022 Results assessing the impact of apremilast in biologic-naive patients with early peripheral PsA presented at the ACR Convergence 2022
  • 20 Dec 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
  • 16 Aug 2021 Planned End Date changed from 15 Jun 2021 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top